Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$37.1 million.

  • Spyre Therapeutics' Cash from Operations fell 2615.82% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.9 million, marking a year-over-year decrease of 702.56%. This contributed to the annual value of -$157.4 million for FY2024, which is 5755.18% down from last year.
  • Spyre Therapeutics' Cash from Operations amounted to -$37.1 million in Q3 2025, which was down 2615.82% from -$46.6 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Cash from Operations high stood at $2.1 million for Q2 2021, and its period low was -$62.2 million during Q2 2024.
  • Over the past 5 years, Spyre Therapeutics' median Cash from Operations value was -$26.3 million (recorded in 2022), while the average stood at -$27.2 million.
  • In the last 5 years, Spyre Therapeutics' Cash from Operations skyrocketed by 11072.48% in 2021 and then plummeted by 109293.95% in 2022.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Cash from Operations stood at -$19.3 million in 2021, then increased by 5.85% to -$18.1 million in 2022, then plummeted by 71.09% to -$31.0 million in 2023, then dropped by 19.86% to -$37.2 million in 2024, then increased by 0.22% to -$37.1 million in 2025.
  • Its Cash from Operations was -$37.1 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$41.0 million in Q1 2025.